Label Changes for:
Xyzal (levocetirizine dihydrochloride) oral solution and tablets
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2011
- vomiting, dysuria, blurred vision, angioedema, paraesthesia, dizziness